Gemifloxacin

Caitlin Soto, PharmD, BCIDP, Edina Avdic, Pharm.D.

INDICATIONS

FDA

  • The brand product Factive is no longer marketed in the U.S., and although FDA approval has not been formally withdrawn, no generic version exists in the U.S. market (FDA notice: Gemifloxacin).

LEGACY/GLOBAL USE

  • Historical FDA indications and typical indications in markets where it remains in use.
    • Community-acquired pneumonia (CAP) caused by S. pneumoniae (including multidrug-resistant strains), H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, or K. pneumoniae
    • Acute bacterial exacerbation of chronic bronchitis (AECB) caused by S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis
      • Reserve fluoroquinolones for acute bacterial exacerbations of chronic bronchitis when other appropriate antibacterial options are unavailable or unsuitable because of potentially disabling and persistent adverse reactions.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 14, 2026